AstraZeneca in $815 Million “High Altitude” Anemia Pill Deal

AstraZeneca made a deal with FibroGen for the rights to the latter’s experimental anemia drug. FG-4592 tricks the body into thinking that the person is at a high altitude and as a result creates extra red blood cells, boosting the amount of iron (and oxygen) circulating in the blood.
Reuters